Vistin Pharma ASA (VISTN) will release its third quarter and YTD 2025 results on Friday 31st of October 2025. Vistin Pharma will host a conference call for all shareholders and interested parties on ...
GLP-1 RAs for type 2 diabetes significantly lower one-year mortality, especially in those also diagnosed with obstructive sleep apnea.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback